With the intention of developing the approved drug Zenapax in other indications, Protein Design Labs Inc. restructured its commercial deal with Hoffmann-La Roche Inc. regaining exclusive worldwide rights in all indications other than organ transplantation. (BioWorld Today)

WASHINGTON - As biotech emerges from the wreckage of what G. Steven Burrill calls the "Sam and Martha sideshow," and as uncertainties over war in Iraq, the new requirements of financial reporting and devalued market capitalizations continue to plaque the industry, there is only one direction left for the industry to go: up.

Only 10 years ago at the Biotechnology Industry Organization's first annual convention in Raleigh and Research Triangle Park, N.C., about 1,400 people attended.